Zusammenfassung
Probiotika wurden wegen fehlender Wirksamkeitsnachweise und wegen der umstrittenen
postulierten Wirkweise der Darmfloramodulation von der Schulmedizin über lange Zeit
abgelehnt. Durch GCP-gerechte klinische Studien konnte für einige Probiotika die Wirksamkeit
in bestimmten Indikationen eindeutig belegt werden. Zudem wurden Wirkmechanismen aufgezeigt,
die Wirkungen von Probiotika auf zellulärer Ebene belegen und das Konzept der „Wiederherstellung
des gestörten intestinalen mikrobiellen Gleichgewichts” ersetzen. Unterschiedliche
Probiotika verfügen über verschiedene Wirkmechanismen und für unterschiedliche Probiotika
ist die klinische Wirksamkeit in verschiedenen Indikationen belegt. Einige Probiotika
stellen heute einen therapeutischen Standard in bestimmten Indikationen dar.
Abstract
Due to the lack of proven efficacy and an unidentified mode of action, probiotics
were dismissed by the traditional medical sector for many years. In the meantime,
the clinical efficacy of some probiotics has clearly been substantiated in GCP-compliant
studies. In addition, modes of action have been demonstrated which prove the effects
of probiotics on a cellular level and replace the concept of “restoring the disturbed
intestinal microbial balance”. Different probiotics have distinct modes of action
and the clinical efficacy of various probiotics has been proven in distinct indications.
Today, some probiotics represent therapeutic standards in certain indications.
Schlüsselwörter
Probiotika - Definitionen - Wirkmechanismen - Indikationen - evidence-based medicine
Key words
Probiotics - definitions - modes of action - indications - evidence-based medicine
Literatur
- 1
C P linius Secundus.
23/24 - 79: Naturalis historiae.
XXVIII
36, 135
- 2
Lilly D M, Stillwell R H.
Probiotics: Growth promoting factors produced by microorganisms.
Science.
1965;
147
747-748
- 3
Parker R B.
Probiotics, the other half of the antibiotic story.
Anim Nutr Health.
1974;
29
4-8
- 4
Fuller R.
Probiotics in man and animals.
J Appl Bacteriol.
1989;
66
365-378
- 5 Havenaar R., Huis in’t Veld JHJ .Probiotics: A general view. Wood BJB The Lactic
Acid Bacteria, Vol. 1: The Lactic Acid Bacteria in Health and Disease London; Elsevier
Applied Sciences 1992: 151-170
- 6
Rembacken B J, Snelling A M, Hawkey P M. et al .
Non-pathogenic Escherichia coli versus mesalazine for treatment of ulceratve colitis:
a randomised trial.
Lancet.
1999;
354
635-639
- 7
Surawicz, CM, Elmer E W. et al .
Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective
study.
Gastroenterology.
1989;
96
981-988
- 8
McFarland L, Surawicz C M, Greenberg R N. et al .
A randomized placebo-controlled trial of Saccharomyces boulardii in combination with
standard antibiotics for Clostridium difficile disease.
JAMA.
1994;
271
1913-1918
- 9
Höchter W, Chase D, Hagenhoff G.
Saccharomyces boulardii bei akuter Erwachsenendiarrhoe.
Münch med Wschr.
1990;
132
188-192
- 10
Gionchetti P F, Rizzello U, Helwig A. et al .
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled
trial.
Gastroenterology.
2003;
124
1202-1209
- 11
Mimura T, Rizzello F, Helwig U. et al .
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent
or refractory pouchitis.
Gut.
2004;
53
108-114
- 12
Guandalini S, Pensabene L, Abu Z ikri M. et al .
Lactobacillus GG administered in oral rehydration solution to children with acute
diarrhoea: a multicenter European trial.
J Pediatr Gastroenterol Nutr.
2000;
30
54-60
- 13
Ratliff T L, Hudson M A, Catalona W J.
Strategy for improving therapy of superficial bladder cancer.
World J Urol.
1991;
9
95-98
- 14
Brugier S, Patte F.
Antagonisme in vitro entre l’Ultra Levure et différentes germes bactériens.
Le Med de Paris.
1975;
4
3-8
- 15 Gedek B. Interaktionen zwischen lebenden Hefezellen und darmpathogenen Escherichia-coli-Keimen. Müller
J, Ottenjann R, Seifert J Ökosystem Darm Heidelberg; Springer Verlag 1989: 135-139
- 16
Guarner F, Malagelada J R.
Gut flora in health and disease.
Lancet.
2003;
360
512-519
- 17 Knoke M, Bernhardt H. Mikroökologie des Menschen. Berlin; Akademie-Verlag 1985
- 18 Lembcke B. Pilze im Darm - Gefahr oder Mythos? Eine Herausforderung ärztlicher
Redlichkeit. Kirchner T, Lembcke B, Kist M Ökosystem Darm VIII Heidelberg; Springer
Verlag 1999: 53-63
- 19
Castex F, Corthier G, Jouver S. et al .
Prevention of experimental pseudomenbranous cecitis by Saccharomyces boulardii: Topographical
histology of the mucosa, bacterial counts, and analysis of toxin production.
Mikroökol Ther.
1989;
19
241-250
- 20
Schlee M, Wehkamp J, Harder J. et al .
Das Probiotikum E. coli Nissle 1917 induziert humanes beta Defensin-2 in Abhängigkeit
von NFKB in intestinalen Epithelzellen.
Z Gastroenterol.
2003;
41
34 (Abstract)
- 21
Schmid M, Fellermann K, Wehmann J. et al .
Die Rolle der Defensine in der Pathogenese chronisch-entzündlicher Darmerkrankungen.
Z Gastroenterol.
2004;
42
333-338
- 22
Buts J P, Bernasconi P, van Craynest M P. et al .
Respose of human and rat small intestinal mucosa to oral administration of Saccharomyces
boulardii.
Pediatr Res.
1986;
20
192-196
- 23
Buts J P, de Keyser N, de Raedemaeker L.
Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release
of polyamines.
Pediatr Res.
1994;
36
522-527
- 24
Jahn H U, Ullrich R, Schneider T. et al .
Immunological and trophical effects of Saccharomyces boulardii on the small intestine
in healthy human volunteers.
Digestion.
1995;
57
95-104
- 25
Zaouche A, Loukil C, de Lagausie P. et al .
Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation, and
intestinal adaptation after small-bowel resection in rats.
Scand J Gastroenterol.
2000;
2
160-165
- 26
Winckler C, Schröder B, Breves G.
Effects of Saccharomyces boulardii, Bacillus cereus var. caron and Bacillus cereus
var. toyoi on epithelial transport functions in pig jejunum.
Z Gastroenterol.
1998;
Suppl. 1
30-37
- 27
Breves G, Walter C, Burmester M. et al .
In vitro studies on the effect of Saccharomyces boulardii and Bacillus cereus var.
toyoi on nutrient transport in pig jejunum.
J Anim Physiol a Anim Nutr.
2000;
84
9-20
- 28
Kamm K, Hoppe S, Breves G. et al .
Effects of the probiotic yeast Saccharomyces boulardii on the neurochemistry of myenteric
neurones in pig jejunum.
Neurogastroenterol Motil.
2004;
16
53-60
- 29
Baum B, Liebler-Tenorio E M, Enß M L. et al .
Saccharomyces boulardii and Bacillus cereus var. toyoi influence the morphology and
the mucins of the intestine of pigs.
Z Gastroenterol.
2002;
40
277-284
- 30
Kuzela L, Kascak M, Vavrecka A.
Induction and maintenance of remission with nonpathogenic Escherichia coli in patients
with pouchitis.
Am J Gastroenterol.
2001;
96
3218-3219
- 31
Stüttgen G.
Aknetherapie mit Saccharomyces boulardii.
Akt Dermatol.
1991;
17
206-209
- 32
Kim H J, Camilleri M, McKenzie S. et al .
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in
diarrhoea-predominant irritable bowel sydrome.
Aliment Pharmakol Ther.
2003;
17
895-904
- 33
Kalliomäki M, Salminen S, Arvilommi H. et al .
Probiotics in primary prevention of atopic disease: a randomised placebo-controlled
trial.
Lancet.
2001;
357
1076-1079
- 34
Ohashi Y, Nakai S, Tsukamoto N. et al .
Habitual intake of lactic acid bacteria and risk reduction of bladder cancer.
Urol Int.
2002;
68
273-280
Dr. H. Holst
Life Sciences Consulting
In den Gärten 12
59348 Lüdinghausen
eMail: HolstConsulting@aol.com
